Anthony M. Turkiewicz

TL;DR: Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.

TL;DR: Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient.

TL;DR: Both the 2-week and 4-week ixekizumab dosing regimens improved the signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate response to tumour necrosis factor inhibitors, with a safety profile consistent with previous studies investigating ixeksedumab.

TL;DR: A subset of patients with PsA fail to respond to conventional therapies and to anti–tumor necrosis factor (anti-TNF) agents that are currently approved for the treatment of PsA, underscoring the diverse mechanisms likely to be at play in these heterogeneous phenotypic subtypes ofPsA.

TL;DR: CZP efficacy was maintained to week 96 with both dose regimens and in patients with/without prior anti-TNF exposure, with no new safety signals observed with increased exposure.